Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linsitinib in metastatic castrate resistant prostate cancer
NCT01533246Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2012
- Primary completion
- Nov 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of linsitinib in prostate cancer (PCa), sponsored by National Cancer Institute. Started Feb 2012; status: completed.
02
Drugs
linsitinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01533246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01533246.